X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
APEX-90 macrodose psilocybin product is being studied for treatment of patients suffering from moderate or severe depression and PTSD in phase 2 clinical trials.
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: Apex-90
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2023
Details:
APEX-90 (psilocybin) is a macrodose formulation which act as agonistically with serotonin (5-hydroxytryptamine) type 2A (5-HT2A) receptors, which is investigated for the treatment of severe depression in patients with diagnosed PTSD.
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: APEX-90
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2023
Details:
NM-1001 (psilocybin) reacts agonistically with serotonin (5-hydroxytryptamine) type 2A (5-HT2A) receptors to produce a “mystical-like” hallucinatory effect due to induced frontal hyper-frontality, which in turn mediates its anti-depressant and anti-anxiety effects.
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: NM-1001
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2023
Details:
APEX-52 (psilocybin) reacts agonistically with serotonin (5-hydroxytryptamine) type 2A (5-HT2A) receptors to produce a “mystical-like” hallucinatory effect due to induced frontal hyper-frontality, which in turn mediates its anti-depressant and anti-anxiety effects.
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: APEX-52
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2023
Details:
APEX-52 microdose, orally administered synthetic psilocybin reacts agonistically with serotonin (5-hydroxytryptamine) type 2A (5-HT2A) receptors to produce a hallucinatory effect. It is being investigated for depression and anxiety among adults diagnosed with PTSD.
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: APEX-52
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2023
Details:
APEX-52 (psilocybin) reacts agonistically with serotonin (5-hydroxytryptamine) type 2A (5-HT2A) receptors to produce a “mystical-like” hallucinatory effect due to induced frontal hyper-frontality, which in turn mediates its anti-depressant and anti-anxiety effects.
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: APEX-52
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2023
Details:
CTA approval for a dose-finding study to evaluate the safety, tolerability, and efficacy of psilocybin in Veterans with post-traumatic stress disorder using drug product APEX-002-A01.
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: APEX-002-A01
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
